SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 143 filers reported holding SAGE THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 0.72 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2019 | $12,444,000 | -32.0% | 88,700 | -11.3% | 0.76% | -28.0% |
Q2 2019 | $18,309,000 | -11.5% | 100,000 | -23.1% | 1.05% | -24.7% |
Q1 2019 | $20,677,000 | -41.3% | 130,000 | -64.6% | 1.40% | -51.1% |
Q4 2018 | $35,226,000 | +31.3% | 367,732 | +93.5% | 2.86% | +64.0% |
Q3 2018 | $26,838,000 | -28.4% | 190,000 | -20.7% | 1.74% | -37.2% |
Q2 2018 | $37,508,000 | -2.8% | 239,619 | 0.0% | 2.78% | -3.5% |
Q1 2018 | $38,595,000 | +75.5% | 239,619 | -67.2% | 2.88% | -7.8% |
Q2 2016 | $21,995,000 | -27.4% | 730,000 | -22.8% | 3.12% | -31.7% |
Q1 2016 | $30,297,000 | +65.0% | 945,000 | +200.0% | 4.56% | +107.7% |
Q4 2015 | $18,365,000 | +80.8% | 315,000 | +31.2% | 2.20% | +35.5% |
Q3 2015 | $10,157,000 | +23520.9% | 240,000 | +28135.3% | 1.62% | +23071.4% |
Q1 2015 | $43,000 | +16.2% | 850 | -15.0% | 0.01% | +16.7% |
Q4 2014 | $37,000 | -88.3% | 1,000 | -90.0% | 0.01% | -90.8% |
Q3 2014 | $315,000 | – | 10,000 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Casdin Capital, LLC | 312,000 | $29,886,000 | 5.11% |
DAFNA Capital Management LLC | 104,306 | $9,991,000 | 4.97% |
Palo Alto Investors LP | 850,977 | $81,515,000 | 4.34% |
BB BIOTECH AG | 1,375,229 | $131,733,000 | 4.22% |
Eventide Asset Management | 936,000 | $89,659,000 | 3.97% |
TRV GP II, LLC | 37,362 | $3,579,000 | 3.56% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 146,179 | $14,002,000 | 2.11% |
SUFFOLK CAPITAL MANAGEMENT LLC | 111,908 | $10,720,000 | 2.06% |
OAK RIDGE INVESTMENTS LLC | 231,483 | $22,174,000 | 1.60% |
Rhenman & Partners Asset Management AB | 137,339 | $13,156,000 | 1.50% |